IT之家 October 8 news: Bloomberg reported today Beijing time that Isomorphic Labs, Alphabet's AI-powered drug development company led by 2024 Nobel Prize in Chemistry laureate Demis Hassabis (戴米斯 · 哈萨比斯), is in early talks regarding a new round of funding.
Isomorphic Labs conducted a Series B funding round in May this year, raising 2.1 billion US dollars (IT之家 note: approx. 14,096 million RMB at current exchange rates) from its parent company and other investors.
The report states that the company's valuation in the new funding round would be at least 40 billion US dollars (approx. 268,498 million RMB at current exchange rates) and could reach 50 billion US dollars (approx. 335,623 million RMB at current exchange rates).
The application of artificial intelligence in biopharmaceuticals is still at an early stage. Although multiple players have already carried out a series of explorations at the conceptual level,a series of efforts are still needed before crossing clinical trials and moving toward final market launch。